Medical Oncology Associates Of Fccc is a Neurology Clinic in Philadelphia, Pennsylvania. It is located at 333 Cottman Ave, Medical Oncology Assoc Of Fccc, Philadelphia, PA and its contact number is 215-728-6900. The authorized person for Medical Oncology Associates Of Fccc is Robert Beck
who is Senior Vice President of the clinic and his/her contact number is 215-214-1490. Other organizations associated with this clinic are Health Services Of Fox Chase Cancer Ctr., Fox Chase Cancer Center Medical Group, Inc, Medical Oncology Associates Of Fccc Clinic has licensed physician, who has additional training, experience, and competence in the standards of performance and interpretation of Magnetic Resonance Imaging (MRI / MRA) of the head, spine, and peripheral nerves, and Computed Tomography (CT) of the head and spine. Neurologists are trained in the administration of contrast media and the recognition and treatment of adverse reactions to contrast media. Neuroimaging training encompasses thorough knowledge of clinical neurology, neurophysiology, neuroanatomy, neurochemistry, neuropharmacology, and dynamics of cerebrospinal fluid circulation. Physicians possess special expertise in the technical aspects and clinical applications of each of the modalities and techniques of neuroimaging.
Complete Clinic Profile:
Medical Oncology Associates Of Fccc Clinic speciality, address, contact phone number and fax are as below.
Patients can call on the below given phone number for appointments.
Name:
Medical Oncology Associates Of Fccc
Specialization:
Neurology
Clinic Address:
333 Cottman Ave, Medical Oncology Assoc Of Fccc, Philadelphia, Pennsylvania, 19111-2434
Phone:
215-728-6900
Fax:
215-214-1405
Authorized/Official Person Profile:
Officially authorized person to contact for any management issues or complaints for this clinic are as below. Person's position and contact details are also mentioned below.
Name:
Robert Beck
Position:
Senior Vice President
Contact Number:
215-214-1490
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details for Medical Oncology Associates Of Fccc clinic are as mentioned below.
NPI Number:
1588692404
NPI Enumeration Date:
29 Jun, 2006
NPI Last Update On:
25 Jan, 2012
Other Associated Organizations:
Other organizations which are associated with this clinic are as mentioned below. These organization share the same address but have similar or different specialization.
Speciality of these organizations are also mentioned below.
Name
Specialization
NPI Number
Health Services Of Fox Chase Cancer Ctr.
Internal Medicine (Infectious Disease)
1588692404
Fox Chase Cancer Center Medical Group, Inc
Internal Medicine (Neurology)
1710251897
Medical Licenses:
Organizations can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Medical Oncology Associates Of Fccc are as mentioned below.
Specialization
License Number
State
Status
Medical Oncology
Primary
Infectious Disease
Secondary
Neurology
Secondary
Special Hospital
Secondary
Other Medical Identifiers:
Other legacy medical identifiers of the clinic such as Medicaid, Medicare PIN, NSC, UPIN etc. are mentioned as below.
Identifier
Type
State
Issuer
00124679400075
Medicaid
Pennsylvania
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
Medical Oncology Associates Of Fccc 333 Cottman Ave, Medical Staff Office Philadelphia, Pennsylvania
Zip:
19111-2434
Phone Number:
215-728-6900
Fax Number:
215-214-1405
Patients can reach Medical Oncology Associates Of Fccc at 333 Cottman Ave, Medical Oncology Assoc Of Fccc, Philadelphia, Pennsylvania or can call to book an appointment on 215-728-6900. *Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 14 October, 2024.